Brought to you by 
Novartis's Ciba Vision to develop eye treatments with QLT
18 May 2000
Executive Summary
Novartis's eye care unit Ciba Vision will partner again with QLT PhotoTherapeutics to develop photodynamic therapies for eye disorders, particularly neovascularization, a growth of abnormal blood vessels in the eye.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis's Ciba Vision to develop eye treatments with QLT
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice